Telix, AU000000TLX2

Telix stock: UBS update highlights diagnostics cash engine

Published on 11/20/2026 at 20:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Telix stock followed a UBS update on November 17 that highlighted diagnostics cash generation and a broader therapeutics strategy. ITM remains a planned acquisition.

Business Shift And Upcoming Catalysts

  • Management presented diagnostics as Telix's cash engine while expanding into therapeutics, manufacturing and isotope supply.
  • The planned ITM transaction is intended to secure lutetium supply and bring ITM-11 forward by about 18 months.
  • The BYPASS Phase III trial could expand the US PSMA imaging market, with data expected in late first quarter or early second quarter of 2027.
Telix, AU000000TLX2, Illustration mit AI erstellt.

Telix Pharmaceuticals used the UBS Global Biopharma Conference on Tuesday, November 17, to outline a shift from a diagnostics-led business toward a broader platform spanning therapeutics, manufacturing and isotope supply. In a report by Investing.com, management said the diagnostics business is on track for about 1 billion US dollars in revenue this year and more than 400 million US dollars in cash flow.

Telix stock traded at 7.72 euros on Lang & Schwarz at 20:28 CET on Friday, November 20, 2026.

Cash Engine Funds Expansion

Chief Executive Christian Behrenbruch said the imaging business remains the company's financial engine. Management said prostate cancer imaging revenue had grown more than 25 percent during the year and that Telix held just over 40 percent of the PSMA imaging market.

Management described third-quarter performance as flat, in line with its plan, while saying the exit into the fourth quarter had been strong. The company also pointed to the BYPASS Phase III program as a potential market-expansion driver. Data are expected in late first quarter or early second quarter of 2027, and management said the program could add almost 1 million scans to the US total addressable market.

ITM Deal Remains Pending

The proposed acquisition of ITM Isotope Technologies Munich has not closed. Management said completion is targeted before the end of 2026, subject to the transaction's closing conditions.

Telix expects the deal to improve access to lutetium supply and add about 800 radiopharmaceutical specialists. Management also said ITM-11 could bring the company's transition into therapeutics forward by about 18 months, while adding potential products and label expansions in neuroendocrine tumours.

Upcoming Development Milestones

Other milestones include the planned resubmission of the Zircaix application before the end of 2026 and further clinical updates across Telix's therapeutic portfolio. Management said 2027 could bring a concentration of regulatory decisions, trial readouts and supply-chain integration.

Telix Pharmaceuticals Limited

  • ISIN: AU000000TLX2
  • Primary listing: ASX
  • Ticker: TLX
  • Lang & Schwarz quote: 7.72 euros at 20:28 CET on November 20, 2026

The Australian market context is covered in the latest S&P/ASX 200 market reports.

More news and analyses on Telix Pharmaceuticals stock

Disclaimer...
en | AU000000TLX2 | TELIX | boerse | 70541043 | bgmi